Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 37/75 ]
NASDAQ | Common Stock
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform.
In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting.
It has licenses and collaboration agreements with Koninklijke PhilipsN. V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC.
The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.
ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 26 | -0.27 Decreased by -35.00% | -0.18 Decreased by -45.95% |
| Nov 6, 25 | -0.21 Decreased by -16.67% | -0.18 Decreased by -16.67% |
| Aug 12, 25 | -0.21 Decreased by -31.25% | -0.20 Decreased by -5.00% |
| May 5, 25 | -0.22 Decreased by -37.50% | -0.16 Decreased by -37.50% |
| Feb 26, 25 | -0.20 Decreased by -5.26% | -0.17 Decreased by -15.14% |
| Nov 7, 24 | -0.18 Increased by +10.00% | -0.17 Decreased by -5.88% |
| Aug 7, 24 | -0.16 Increased by +44.83% | -0.20 Increased by +20.00% |
| May 7, 24 | -0.16 Increased by +30.43% | -0.19 Increased by +15.79% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 10.41 M Increased by +33.96% | -7.79 M Decreased by -44.56% | Decreased by -74.79% Decreased by -7.91% |
| Sep 30, 25 | 8.86 M Increased by +9.10% | -5.89 M Decreased by -18.44% | Decreased by -66.48% Decreased by -8.56% |
| Jun 30, 25 | 9.21 M Increased by +17.27% | -5.84 M Decreased by -32.42% | Decreased by -63.34% Decreased by -12.92% |
| Mar 31, 25 | 8.48 M Increased by +11.07% | -6.03 M Decreased by -45.34% | Decreased by -71.02% Decreased by -30.85% |
| Dec 31, 24 | 7.77 M Increased by +14.11% | -5.39 M Decreased by -16.61% | Decreased by -69.31% Decreased by -2.19% |
| Sep 30, 24 | 8.12 M Increased by +40.96% | -4.97 M Decreased by -3.43% | Decreased by -61.24% Increased by +26.62% |
| Jun 30, 24 | 7.86 M Increased by +32.07% | -4.41 M Increased by +37.49% | Decreased by -56.10% Increased by +52.67% |
| Mar 31, 24 | 7.64 M Increased by +40.60% | -4.15 M Increased by +26.08% | Decreased by -54.27% Increased by +47.43% |